allogeneic hematopoietic stem cell transplantation-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-acute myeloid leukemia

This therapeutic protocol, "allogeneic hematopoietic stem cell transplantation-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-acute myeloid leukemia," refers to an upfront allogeneic hematopoietic stem cell transplantation (HSCT) strategy for elderly patients (aged 65-75) with acute myeloid leukemia (AML). Developed and evaluated by the Fondazione Policlinico Universitario Agostino Gemelli IRCCS, the approach involves performing a transplant early in the disease course, either without prior induction therapy or following a single short course of chemotherapy (cytarabine and anthracycline). The conditioning regimen typically utilizes a Thiotepa-Busulfan-Fludarabine (TBF) protocol, which is dose-adjusted based on the patient's age and clinical fitness. The primary objective of this strategy is to achieve higher complete remission rates and improve overall disease-free survival in a high-risk patient population that often responds poorly to conventional treatments like demethylating agents or intensive chemotherapy.

Other names

Up-front allogeneic hematopoietic stem cell transplantationUp-front HSCT in Elderly AMLUp-front allogeneic hematopoietic stem cell transplantation (HSCT)